We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Portable Test Uses CRISPR to Rapidly Identify STIs and Resistance Markers

By LabMedica International staff writers
Posted on 30 Mar 2026

Sexually transmitted infections are increasing, straining clinic capacity and delaying treatment when patients must return for results. More...

Many settings lack rapid on‑site diagnostics, and current workflows often require multiple samples and separate tests. Researchers have now developed a portable gene‑targeting platform designed for rapid, point‑of‑care (POC) identification of common infections. The approach aims to shorten time to diagnosis and enable single‑visit management.

The device is a rapid POC test built on clustered regularly interspaced short palindromic repeats (CRISPR) technology. Developed by researchers at the Peter Doherty Institute for Infection and Immunity (Melbourne, Australia), it is described as the first platform able to detect all major bacterial sexually transmitted infections, including syphilis, on a single system in under an hour. The platform consolidates testing within routine clinic encounters.

The assay operates in two stages. It first amplifies target genetic material from a urine or genital‑swab specimen at a constant warm temperature using isothermal amplification, avoiding thermal cycling equipment used in polymerase chain reaction (PCR). It then applies a CRISPR‑Cas system in which a programmed guide ribonucleic acid (RNA) directs a Cas enzyme to pathogen DNA or RNA; target recognition activates collateral cleavage of reporter molecules, generating a detectable signal.

The platform can run multiple Cas enzymes and guide RNAs simultaneously, enabling multiplex screening from a single sample. In sexually transmitted infection care, this means clinicians do not need to choose between tests for herpes or syphilis. The instrument reports which infections are present, supporting streamlined evaluation.

Beyond detection, the system interrogates a genetic marker of antibiotic resistance in gonorrhea. This capability can support faster selection of an effective antibiotic rather than empiric prescribing while waiting for conventional results. As resistance to standard gonorrhea treatments increases globally, targeted prescribing information becomes more valuable in everyday practice.

The public‑health need is pressing. In August 2025, Australia’s Chief Medical Officer designated syphilis a Communicable Disease Incident of National Significance, reflecting rising infections. National surveillance indicates infectious syphilis diagnoses have more than doubled over the past decade, with 6,000 cases recorded in 2024. Increasing rates among heterosexuals, including women of reproductive age, heighten risks such as infertility, miscarriages, and congenital syphilis.

The developers note that access to testing is often constrained in rural and remote areas and that multiple‑visit pathways impede timely treatment, even in urban clinics. The portable CRISPR‑based tests are presented as a practical addition to improve detection and management across Australia. The team also envisions future use with self‑collected samples, alongside continued emphasis on clinician education, culturally safe care, and equitable access to services.

Related Links
Doherty Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.